| Adam J Landsdorf, MD | |
|
1150 Veterans Blvd, Redwood City, CA 94063-2037 | |
| (650) 299-2000 | |
| Not Available |
| Full Name | Adam J Landsdorf |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 1150 Veterans Blvd, Redwood City, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134207798 | NPI | - | NPPES |
| 00A712650 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A71265 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced Phase I clinical trial results for Protexia, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents.
Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.
The U.S. Food and Drug Administration today announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.
The older we get, the more different we become. This is the conclusion of a study that followed people from their 70th to their 90th year of life.
An incurable, paralyzing disease in humans is now genetically linked to a similar disease in dogs.
› Verified 3 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced Phase I clinical trial results for Protexia, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents.
Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.
The U.S. Food and Drug Administration today announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.
The older we get, the more different we become. This is the conclusion of a study that followed people from their 70th to their 90th year of life.
An incurable, paralyzing disease in humans is now genetically linked to a similar disease in dogs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam J Landsdorf, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (510) 625-6262 | Adam J Landsdorf, MD 1150 Veterans Blvd, Redwood City, CA 94063-2037 Ph: (650) 299-2000 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced Phase I clinical trial results for Protexia, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents.
Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.
The U.S. Food and Drug Administration today announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.
The older we get, the more different we become. This is the conclusion of a study that followed people from their 70th to their 90th year of life.
An incurable, paralyzing disease in humans is now genetically linked to a similar disease in dogs.
› Verified 3 days ago
Sean Edwin Bourke, M.D Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 170 Alameda De Las Pulgas, Redwood City, CA 94062 Phone: 650-369-5811 | |
Derek William Altema, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 450 Broadway St # Mc6342, Redwood City, CA 94063 Phone: 650-721-1446 | |
Kirsten M. Stewart, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1150 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-2000 | |
Andrea G. Roberts, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1150 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-2000 | |
George Bulloch Iii, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1150 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-2000 | |
Dimyana A Abdelmalek, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1100 Veterans Blvd, Redwood City, CA 94063 Phone: 650-299-2000 |